The cellular therapy from Israel’s Kadimastem (see here previously) was able to slow down the progression of ALS in its first human clinical trial on ten patients. Kadimastem’s Vice President of R&D Michal Izrael describes the treatment and the next … Continue reading →

As reported (here) previously, the stem cell ALS therapy developed by Israel’s Kadimastem showed promise in the lab. Now, early results from human trials at Hadassah hospital in Jerusalem show that it has significantly slowed down disease progression without major … Continue reading →

The US FDA has just given Orphan status to the ALS treatment being developed by Israel’s Kadimastem (see here). The designation qualifies the company for various development incentives and less rigorous bureaucracy. Kadimastem expects results of its Israeli clinical trials … Continue reading →

Israel’s Kadimastem is partnering with France’s Defymed to develop a stem cell-based bio-artificial pancreas for the treatment of type 1 diabetes. They received NIS 5.4 million from the European Commission and the intergovernmental research organization EUREKA. https://www.calcalistech.com/ctech/articles/0,7340,L-3749642,00.html

Israel’s Kadimastem’s recent news includes success in pre-clinical tests of its stem cell treatment for ALS. The technology also induces pancreatic cells to produce insulin and Kadimastem has begun research with Ramot, Tel Aviv University’s technology transfer company. http://www.israel21c.org/headlines/stem-cell-therapy-for-als-diabetes/

(Thanks to Atid-EDI) Israel’s Kadimastem is to work with giant Merck to conduct screening for new treatments into Multiple Sclerosis and other neurodegenerative diseases. Kadimastem’s revolutionary technology uses stem cells to produce cells that protect or repair brain function. http://www.kadimastem.com/press-item/60/kadimastem-to-collaborate-merck-serono-advance-combined-efforts-in-neurodegenerative-disease-area

Whilst at Israel’s Weizmann Institute, molecular geneticist Professor Michel Revel developed treatments for MS, ALS and diabetes. Now at 75 years of age, he works at his biotech Kadimastem developing pluripotent stem cells as a regenerative medicine solution for all … Continue reading →

Israel’s Kadimastem is turning stem cells into beta cells that can produce insulin in the pancreas or nerve cells in the brain. Israel’s Office of the Chief Scientist has just given Kadimastem an NIS 8.5 million grant to continue its … Continue reading →